Basel Medical Group Ltd
corporate_fare Company Profile
Basel Medical Group Ltd (NASDAQ:BMGL) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 13 items for BMGL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-30, rated 8/10. Across its 13 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for BMGL spans 20-F, 424B4, F-1/A, F-1.
Recent high-impact activity:
- Basel Medical FY2026: Revenue Up 45% to S$16.4M, But Material Weakness and Going-Concern Dependency Disclosed
- Basel Medical Finalizes $7.98M Unit Offering at $1.33 — Zero-Cash Warrants Could Add 6M Shares
- Basel Medical Prices 6M-Unit Offering at $1.33 with Zero-Cash Warrants
- Basel Medical Group Files to Sell Up to 6M Units with Warrants
- Basel Medical Files F-1 for Up to 6M Units with Zero-Cash Warrants
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 107,869 shares in BMGL as of the October 30, 2026 settlement, a 731.6% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 45.0% of BMGL volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for BMGL, detected from its recent SEC filings · based on capital-structure filings through 2026-10-08.
6M-Unit Offering Finalized at $1.33 · Zero-Cash Warrants Add 6M More Shares
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
BMGL files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.